Medication info
Tragliptin Duo Tablet 2.5/500 mg

Tragliptin Duo Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval film-coated tablet with a double convex shape
Packaging
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201902169 · Approved 2019.04.09 · Insurance code 653806280

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Drug Must Not Be Administered).

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar in patients with type 2 diabetes by combining Linagliptin and Metformin. It is administered as an adjunct to dietary and exercise therapy to effectively improve blood sugar levels.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Drug Must Not Be Administered).

Precautions

This medication contains Metformin hydrochloride, which can cause serious side effects such as lactic acidosis, and caution is required. Lactic acidosis is rare but can be fatal, so this medication should be discontinued in the event of sudden kidney function deterioration, cardiovascular disease, infections, or other risky situations. Additionally, this medication should not be administered to certain patients, such as those with allergies to its components, type 1 diabetes patients, patients with severe renal impairment, those in acute alcohol intoxication, pregnant women, or nursing mothers. When using this medication, there is a risk of hypoglycemia, especially when combined with other antidiabetic agents, so careful monitoring of blood sugar status is necessary. Immediate appropriate measures should be taken if hypoglycemic symptoms occur. Since kidney function plays an important role, routine kidney function tests should be performed before and during treatment, and if kidney function declines, discontinuation or dosage adjustment may be necessary. Patients with impaired heart function should use this medication with caution, and administration should generally be avoided in cases of acute cardiac disease or heart failure. Using this medication in conjunction with iodinated contrast agents used during radiological examinations can increase the risk of renal dysfunction and lactic acidosis, so this medication should be discontinued for a certain period before and after the examination. Patients scheduled for surgery should discontinue this medication 48 hours before the operation and resume only after confirming normal recovery of kidney function post-surgery. During the use of this medication, acute pancreatitis or skin diseases such as bullous pemphigoid may occur, so if symptoms such as abdominal pain, skin rash, or blisters appear, it is advisable to consult a doctor immediately. The Metformin component may decrease vitamin B12 levels, so regular checks for vitamin B12 deficiency are necessary in cases of prolonged use. It is recommended that women who are pregnant or planning to become pregnant do not use this medication, and it should also be avoided during breastfeeding. The safety and efficacy of this medication have not been established for children under 10 years of age and adolescents, so it is not recommended for them. Elderly patients are more likely to have decreased kidney function, so it is important to monitor kidney function frequently and to provide treatment at the minimum effective dose. This medication may interact with other drugs, so if other medications are being taken, it is essential to inform the doctor or pharmacist. In case of overdose, lactic acidosis may occur, requiring immediate hospitalization for treatment, and blood dialysis may be necessary. For storage, it should be kept out of reach of children, protected from moisture, and stored in its original container to maintain efficacy.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 118 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • oral ulcer
  • hepatitis
  • liver function abnormalities
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • epistaxis
  • oropharyngeal pain
  • dysphonia
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • viral upper respiratory infection
  • periodontitis
  • folliculitis
  • gingivitis
  • influenza
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • pruritus
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container, protected from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. By doing so, the effectiveness of the medication can be preserved for a long time.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablet with a double convex shape

Package unit

10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.